These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 18562053)

  • 1. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals.
    Liu J; Yu Q; Stone GW; Yue FY; Ngai N; Jones RB; Kornbluth RS; Ostrowski MA
    Vaccine; 2008 Jul; 26(32):4062-72. PubMed ID: 18562053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals.
    Yu Q; Gu JX; Kovacs C; Freedman J; Thomas EK; Ostrowski MA
    J Immunol; 2003 Feb; 170(4):1797-805. PubMed ID: 12574344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques.
    Silva de Castro I; Gordon SN; Liu J; Bissa M; McKinnon K; Trinh HV; Doster MN; Schifanella L; Liyanage NP; Cao J; Cheng O; Foulds K; Roederer M; Koup RA; Shen X; Tomaras GD; Venzon DJ; Forthal DN; Fouts T; Montefiori DC; Tartaglia J; Rao M; Ostrowski M; Franchini G; Vaccari M
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31896599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals.
    Engelmayer J; Larsson M; Lee A; Lee M; Cox WI; Steinman RM; Bhardwaj N
    J Virol; 2001 Mar; 75(5):2142-53. PubMed ID: 11160718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of TNFSF as molecular adjuvants for ALVAC HIV-1 vaccines.
    Liu J; Ostrowski M
    Hum Vaccin; 2010 Apr; 6(4):355-9. PubMed ID: 20372075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.
    Stone GW; Barzee S; Snarsky V; Kee K; Spina CA; Yu XF; Kornbluth RS
    J Virol; 2006 Feb; 80(4):1762-72. PubMed ID: 16439533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
    Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
    Front Immunol; 2021; 12():786144. PubMed ID: 35095862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells.
    Marovich MA; Mascola JR; Eller MA; Louder MK; Caudrelier PA; El-Habib R; Ratto-Kim S; Cox JH; Currier JR; Levine BL; June CH; Bernstein WB; Robb ML; Schuler-Thurner B; Steinman RM; Birx DL; Schlesinger-Frankel S
    J Infect Dis; 2002 Nov; 186(9):1242-52. PubMed ID: 12402193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
    Belshe RB; Gorse GJ; Mulligan MJ; Evans TG; Keefer MC; Excler JL; Duliege AM; Tartaglia J; Cox WI; McNamara J; Hwang KL; Bradney A; Montefiori D; Weinhold KJ
    AIDS; 1998 Dec; 12(18):2407-15. PubMed ID: 9875578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of antigen-specific immune responses induced by canarypox virus vaccines.
    Bos R; van Duikeren S; van Hall T; Lauwen MM; Parrington M; Berinstein NL; McNeil B; Melief CJ; Verbeek JS; van der Burg SH; Offringa R
    J Immunol; 2007 Nov; 179(9):6115-22. PubMed ID: 17947686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy.
    Ferrari G; Berend C; Ottinger J; Dodge R; Bartlett J; Toso J; Moody D; Tartaglia J; Cox WI; Paoletti E; Weinhold KJ
    Blood; 1997 Sep; 90(6):2406-16. PubMed ID: 9310492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.
    Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G
    Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD40 ligand enhances immunogenicity of vector-based vaccines in immunocompetent and CD4+ T cell deficient individuals.
    Auten MW; Huang W; Dai G; Ramsay AJ
    Vaccine; 2012 Apr; 30(17):2768-77. PubMed ID: 22349523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
    Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
    J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene.
    Egan MA; Pavlat WA; Tartaglia J; Paoletti E; Weinhold KJ; Clements ML; Siliciano RF
    J Infect Dis; 1995 Jun; 171(6):1623-7. PubMed ID: 7769304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
    Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic T-lymphocyte responses to canarypox vector-based HIV vaccines in HIV-seronegative individuals: a meta-analysis of published studies.
    Edupuganti S; Weber D; Poole C
    HIV Clin Trials; 2004; 5(5):259-68. PubMed ID: 15562366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
    Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M
    Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV.
    Zhang R; Zhang S; Li M; Chen C; Yao Q
    Vaccine; 2010 Jul; 28(31):5114-27. PubMed ID: 20471443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.